Health

St. Joseph's Children's Hospital Foundation Receives Historic $50 Million Gift from the Pagidipati Family of Tampa

TAMPA, Fla., April 11, 2024 /PRNewswire/ -- St. Joseph's Children's Hospital Foundation announced today a$50 million gift from the Pagidipati family of Tampa to support the future of pediatric health care in theTampa Bay community. Tampa business leader and philanthropistSidd Pagidipati, along wi...

2024-04-11 09:18 1215

CSafe unveils cutting-edge innovations to meet cold chain customer needs

The company will launch three new technologies at the upcoming LogiPharma 2024 event MONROE, Ohio, April 10, 2024 /PRNewswire/ -- CSafe, a leading active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, announces it is launching three new technol...

2024-04-10 22:50 1734

Development of exosome therapy to treat inflammatory bowel disease by VesiCURE Therapeutics

SUZHOU, China, April 10, 2024 /PRNewswire/ -- IBD, or Inflammatory Bowel Disease, traditionally more prevalent in developed nations, is increasingly observed in developing regions likeChina. It is a chronic, nonspecific inflammatory gastrointestinal disorder with an unknown etiology, characterize...

2024-04-10 21:15 1099

ACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research

NEWARK, Del., April 10, 2024 /PRNewswire/ -- Starting in 2023, ACROBiosystems has been continuously rolling out a series of innovative organoid-related products. At a range of significant international events, including the 2024 International Organoid Summit, the Alzheimer's Research UK Conferenc...

2024-04-10 21:00 1172

3Shape Charts Sustainable Course with Release of Comprehensive Sustainability Report 2023

Highlighted in the company's latest report, 3Shape plans to inspire sustainability awareness in the dental industry through its new 5-year sustainability plan. COPENHAGEN, Denmark, April 10, 2024 /PRNewswire/ -- 3Shape, the global innovator in digital dentistry, is proud to unveil its 2023 Susta...

2024-04-10 18:29 1186

Leading the Way: Nicklaus Children's Hospital Awarded Global Healthcare Accreditation with Excellence for Pediatric Medical Travel Services

MIAMI, April 10, 2024 /PRNewswire/ -- Nicklaus Children's Hospital in Miami, Florida, proudly announces its achievement of Global Healthcare Accreditation (GHA) with Excellence for Medical Travel Services. This is Nicklaus Children's Hospital's second GHA Accreditation with Excellence, a distinct...

2024-04-10 18:00 1200

MGI Tech Presents Latest Storage Product Series at ISBER 2024

MELBOURNE, Australia, April 10, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technology to lead life science, today showcased its latest storage solutions catering to a variety of sample storage needs, including MGICLab-LT*, MGICLab-LN55K*, and M...

2024-04-10 17:18 1526

Tsingke Showcases Cutting-Edge Biologics Solutions at Biologics 2024

BEIJING and PARIS, April 10, 2024 /PRNewswire/ -- On March 15th, Biologics 2024 successfully concluded inLondon, with 650 pharmaceutical, biotechnology, and academic representatives and over 50 exhibitors engaging in high-level discussions on the latest innovations in biologics discovery and deve...

2024-04-10 14:19 873

ACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research

TOKYO, April 10, 2024 /PRNewswire/ -- Starting in 2023, ACROBiosystems has been launching a continuous stream of innovative organoid-related products. Displaying their advancements at key global forums including the 2024 International Organoid Summit, Alzheimer's Research UK Conference 2024, and ...

2024-04-10 14:05 1458

R&D Progress: Enrollment of Subjects in Phase III Clinical Trial for Inhaled Aerosol Drug in Children by Kexing Biopharm

SHENZHEN, China, April 10, 2024 /PRNewswire/ -- Recently, Kexing Biopharm (688136.SH) announced that the Phase III clinical trial of Human Interferon α1b Inhalation Solution developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., had completed the enrollment of first p...

2024-04-10 11:41 1740

Alphamab Oncology Presented the Dose-escalation Results from JSKN003 in Patients with Advanced/Metastatic Solid Tumors at AACR

* The dose-escalation results of JSKN003 was reported at this AACR conference. * JSKN003 exhibited a favorable tolerability, safety profile and encouraging preliminary antitumor activity in patients with HER2-expressing advanced/metastatic solid tumors. The ORR in patients with HER2+ BC was 100...

2024-04-10 08:40 1522

Neoss Integrate Australia 2024 - Integrate. Educate. Celebrate

QUEENSLAND, Australia, April 9, 2024 /PRNewswire/ -- This summer, Neoss Australia &New Zealand are celebrating 20 years of Intelligent Simplicity and invites the dental community to join us for an exceptional scientific program with over 21 speakers across two days. Taking place on the Gold Coas...

2024-04-09 23:24 1262

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held fromMarch 29th toApril 1st, 2024, in Shenzhen, China. The TICSSO was initiated by Prof. Xinghua Pan (Southern Medical University), Prof. Fuchou Tang (Peking Un...

2024-04-09 23:14 1391

BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3

SHANGHAI, April 9, 2024 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC2027. BC2027, which is BioCity's second first-in-class antibody drug conjugate (...

2024-04-09 22:10 1089

Datasea Announces Intent of its CEO to Purchase Up $3,000,000 of its Common Stock in Open Market Purchases

BEIJING, April 9, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a digital technology company incorporated inNevada, dedicated to innovative business in acoustic high tech and 5G-Artificial Intelligence multimodal communication technology inthe United States and Ch...

2024-04-09 22:00 3171

Meeting the Future | TIANMA Makes a Strong Appearance at 2024 Embedded World

NUREMBERG, Germany, April 9, 2024 /PRNewswire/ -- The world's largest embedded exhibition—— Embedded World 2024, is being held grandly at the Exhibition Centre Nuremberg from 9th to 11th April. Numerous leading companies around the world have brought exciting technologies and innovative services....

2024-04-09 22:00 1087

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine

GAITHERSBURG, Md., April 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2024-04-09 20:00 1157

Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

BEIJING, SHANGHAI, and SAN DIEGO, April 9, 2024 /PRNewswire/ -- Jacobin Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that the company will present the results of two preclinical evaluation of PARP7 inhibitor JAB-26766 and p53 Y220C reactivat...

2024-04-09 19:59 857

GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting

SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today unveiled the latest research findings of GFH375, an oral KRAS G12D (ON/OFF) inhibitor, at the poster presentatio...

2024-04-09 19:00 992

GenFleet Therapeutics Announces Broad-spectrum Activity of GFH547, an Oral panRAS (ON) Inhibitor, and Its Potential to Overcome Resistance against SIIP-based KRAS Inhibitors in Late-breaking Research Abstract of 2024 AACR Annual Meeting

SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the latest findings of GFH547, an oral panRAS (ON) inhibitor, in a late-breaking research abstract at ...

2024-04-09 19:00 1324
1234567 ... 817